+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neoantigen Cancer Vaccine Market by Neoantigen Type (Personalized Neoantigens, Shared Neoantigens), Therapeutic Target (Immune Checkpoint Blockade, Tumor Neoantigens), Vaccine Platform, Administration Route, End User - Global Forecast 2025-2030- Product Image
Neoantigen Cancer Vaccine Market by Neoantigen Type (Personalized Neoantigens, Shared Neoantigens), Therapeutic Target (Immune Checkpoint Blockade, Tumor Neoantigens), Vaccine Platform, Administration Route, End User - Global Forecast 2025-2030- Product Image
Sale

Neoantigen Cancer Vaccine Market by Neoantigen Type (Personalized Neoantigens, Shared Neoantigens), Therapeutic Target (Immune Checkpoint Blockade, Tumor Neoantigens), Vaccine Platform, Administration Route, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925178
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers seeking actionable insights into next-generation oncology therapeutics will find the neoantigen cancer vaccine market uniquely positioned at the intersection of precision immunotherapy and rapidly evolving clinical practice. The market’s trajectory reflects a convergence of scientific progress, regulatory adaptation, and shifting global dynamics driving personalized treatment strategies.

Market Snapshot: Neoantigen Cancer Vaccine Market Overview

The Neoantigen Cancer Vaccine Market grew from USD 378.66 million in 2024 to USD 434.55 million in 2025. It is projected to expand at a CAGR of 15.01%, reaching USD 876.78 million by 2030. This sustained growth is underpinned by increasing clinical adoption of personalized immunotherapies, technological advancements in sequencing, and expanding global research pipelines in the cancer immunotherapy sector. The combination of industry alliances, adaptive regulatory pathways, and diversified vaccine platforms underscores a robust and competitive market environment.

Scope & Segmentation: Defining the Neoantigen Space

  • Neoantigen Types: Personalized neoantigens (including immune escape and somatic mutations) and shared neoantigens (affinity peptides and common tumor mutations) are key product segments.
  • Therapeutic Targets: Incorporates immune checkpoint blockade (CTLA-4 and PD-1 inhibitors) and tumor neoantigen categories covering mutated and non-mutated antigens.
  • Vaccine Platforms: Cell-based (dendritic cell, T-cell), DNA-based (circular DNA, plasmid DNA), peptide-based (long, synthetic), and RNA-based (mRNA and next-generation RNA) vaccine technologies structure the competitive landscape.
  • Administration Routes: Intradermal, intravenous, oral, and subcutaneous delivery methods address logistical and patient-centric needs.
  • End Users: Cancer treatment centers, hospitals, and research institutes are primary market stakeholders for both therapeutic and research applications.
  • Regional Coverage: The Americas, Europe, Middle East & Africa, and Asia-Pacific. Key attention to US-leading innovation hubs, EU harmonization efforts, and Asia-Pacific's expanding biomanufacturing capacity enhances regional strategy development.
  • Leading Companies: Key participants include Agenus Inc., AstraZeneca PLC, BioNTech SE, Gilead Sciences, Inc., Moderna, Inc., and Merck & Co., Inc., alongside a range of innovative biotechnology firms and academic-industry collaborations.

Key Takeaways: Strategic Insights for Decision-Makers

  • Neoantigen vaccine development is increasingly driven by advances in genomic sequencing and machine learning, enabling precise and individualized therapy design.
  • Manufacturers are optimizing scalable mRNA synthesis and peptide production to improve efficiency and product consistency across the development pipeline.
  • Regulatory bodies in major markets are adapting their frameworks to accommodate rapidly evolving personalized therapeutics, supporting faster clinical trial enrollment and review cycles.
  • Strategic alliances between established pharmaceutical firms and agile biotech players are fueling breakthroughs in both technology development and commercialization pathways.
  • Diverse administration routes and tailored end-user logistics are enhancing product accessibility and broadening the patient base for neoantigen immunotherapies.
  • Region-specific regulatory and reimbursement strategies are necessary for market entry, particularly across the EU, Middle East, and Asia-Pacific regions where policies and adoption vary.

Tariff Impact: U.S. Regulatory Changes and Supply Chain Realignment

The 2025 implementation of new United States tariffs is set to affect the supply chain for neoantigen cancer vaccines. Increased duties on peptide synthesis reagents, nucleic acid precursors, and lipid components are projected to elevate input costs and impact procurement processes. In response, manufacturers are pursuing alternative sourcing strategies, strategic inventory management, and robust supplier relationships to maintain operational resilience and production continuity. These changes may drive adaptation in pricing models as the industry seeks to balance cost and broad patient access.

Methodology & Data Sources

This report employs a rigorous methodology blending primary interviews with industry experts—including oncologists, regulatory professionals, and production specialists—with extensive secondary research drawn from peer-reviewed journals and industry filings. Data triangulation and expert panel validation ensure reliable, actionable insights relevant to strategic decision-making in the neoantigen vaccine sector.

Why This Report Matters

  • Empowers executive leadership with strategic market intelligence to guide investment, partnership, and R&D prioritization for personalized cancer vaccine initiatives.
  • Provides detailed segmentation, enabling high-precision analysis of therapeutic targets, platform technologies, and shifting regional adoption dynamics.
  • Informs risk mitigation strategies related to supply chain disruptions and regulatory changes, supporting operational resilience and competitive positioning.

Conclusion

The neoantigen cancer vaccine market is advancing toward broader clinical impact through strategic collaboration, technological innovation, and adaptive operations. Informed decision-making and agile ecosystem partnerships will define success as personalized immunotherapies reshape oncology care worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of AI-driven neoantigen identification platforms to enhance personalized vaccine design
5.2. Adoption of multiplexed immunopeptidomics to improve neoantigen discovery accuracy in trials
5.3. Emergence of mRNA-based neoantigen vaccine platforms advancing rapid manufacturing timelines
5.4. Collaboration between biotech and academic centers to accelerate neoantigen clinical validation processes
5.5. Increasing investment in personalized neoantigen vaccine programs targeting melanoma and lung cancer
5.6. Focus on combining neoantigen vaccines with checkpoint inhibitors to boost therapeutic efficacy in solid tumors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neoantigen Cancer Vaccine Market, by Neoantigen Type
8.1. Introduction
8.2. Personalized Neoantigens
8.2.1. Immune Escape Mutations
8.2.2. Somatic Mutations
8.3. Shared Neoantigens
8.3.1. Affinity Peptides
8.3.2. Common Tumor Mutations
9. Neoantigen Cancer Vaccine Market, by Therapeutic Target
9.1. Introduction
9.2. Immune Checkpoint Blockade
9.2.1. CTLA-4 Inhibitors
9.2.2. PD-1 Inhibitors
9.3. Tumor Neoantigens
9.3.1. Mutated Neoantigens
9.3.2. Non-Mutated Neoantigens
10. Neoantigen Cancer Vaccine Market, by Vaccine Platform
10.1. Introduction
10.2. Cell-Based Vaccines
10.2.1. Dendritic Cell Vaccines
10.2.2. T-Cell Vaccines
10.3. DNA-Based Vaccines
10.3.1. Circular DNA Platforms
10.3.2. Plasmid DNA Vaccines
10.4. Peptide-Based Vaccines
10.4.1. Long Peptides
10.4.2. Synthetic Peptides
10.5. RNA-Based Vaccines
10.5.1. mRNA Vaccines
10.5.2. Next-Gen RNA Platforms
11. Neoantigen Cancer Vaccine Market, by Administration Route
11.1. Introduction
11.2. Intradermal
11.3. Intravenous
11.4. Oral
11.5. Subcutaneous
12. Neoantigen Cancer Vaccine Market, by End User
12.1. Introduction
12.2. Cancer Treatment Centers
12.3. Hospitals
12.4. Research Institutes
13. Americas Neoantigen Cancer Vaccine Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Neoantigen Cancer Vaccine Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Agenus Inc.
16.3.2. AstraZeneca PLC
16.3.3. Avidea Technologies
16.3.4. Ayala Pharmaceuticals, Inc.
16.3.5. BioLineRx Ltd.
16.3.6. BioNTech SE
16.3.7. BioVaxys Technology Corp.
16.3.8. Brightpath Biotherapeutics Co., Ltd.
16.3.9. CureVac N.V.
16.3.10. Elicio Therapeutics Inc
16.3.11. F. Hoffmann-La Roche Ltd.
16.3.12. Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
16.3.13. Genocea Biosciences Inc
16.3.14. GenScript Biotech Corporation
16.3.15. Gilead Sciences, Inc.
16.3.16. Gritstone bio, Inc.
16.3.17. Immunomic Therapeutics, Inc.
16.3.18. ISA Pharmaceuticals B.V.
16.3.19. Medigene AG
16.3.20. Merck & Co., Inc.
16.3.21. Moderna, Inc.
16.3.22. Neophore Limited
16.3.23. Nouscom AG
16.3.24. Nykode Therapeutics ASA
16.3.25. OSE Immunotherapeutics
16.3.26. Takis S.r.l.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. NEOANTIGEN CANCER VACCINE MARKET: RESEARCHAI
FIGURE 26. NEOANTIGEN CANCER VACCINE MARKET: RESEARCHSTATISTICS
FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET: RESEARCHCONTACTS
FIGURE 28. NEOANTIGEN CANCER VACCINE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 153. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 154. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 155. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 156. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 157. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 158. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 159. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 160. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 161. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 162. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 163. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 164. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 165. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 166. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 167. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 168. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 169. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 170. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 171. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 172. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 173. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 174. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 175. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 176. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 177. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 180. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 181. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 182. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 183. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 184. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 185. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 186. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 187. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 188. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 192. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 193. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 194. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 195. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 196. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 197. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 198. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 199. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 200. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 201. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 202. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 203. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Neoantigen Cancer Vaccine market report include:
  • Agenus Inc.
  • AstraZeneca PLC
  • Avidea Technologies
  • Ayala Pharmaceuticals, Inc.
  • BioLineRx Ltd.
  • BioNTech SE
  • BioVaxys Technology Corp.
  • Brightpath Biotherapeutics Co., Ltd.
  • CureVac N.V.
  • Elicio Therapeutics Inc
  • F. Hoffmann-La Roche Ltd.
  • Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • Genocea Biosciences Inc
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Gritstone bio, Inc.
  • Immunomic Therapeutics, Inc.
  • ISA Pharmaceuticals B.V.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neophore Limited
  • Nouscom AG
  • Nykode Therapeutics ASA
  • OSE Immunotherapeutics
  • Takis S.r.l.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 434.55 Million
Forecasted Market Value ( USD ) by 2030 $ 876.78 Million
Compound Annual Growth Rate15.0%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Neoantigen Cancer Vaccines - Global Strategic Business Report - Product Image

Neoantigen Cancer Vaccines - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Neoantigen Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Neoantigen Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Neoantigen-Based Personalized Cancer Therapeutic Vaccines - Pipeline Insight, 2025 - Product Image

Neoantigen-Based Personalized Cancer Therapeutic Vaccines - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Cancer Vaccines Market by Type, Technology, Indication, ROA, End User - Global Forecast to 2032 - Product Image

Cancer Vaccines Market by Type, Technology, Indication, ROA, End User - Global Forecast to 2032

  • Report
  • 263 Pages
  • Global
From
Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence - Product Image

Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence

  • Directory
  • Global
From

About the Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine market is a subset of the larger Cancer Vaccine market. Neoantigen Cancer Vaccines are a type of personalized cancer immunotherapy that uses a patient’s own tumor-specific mutations to create a vaccine tailored to their individual cancer. These vaccines are designed to stimulate the patient’s immune system to recognize and attack cancer cells. Neoantigen Cancer Vaccines are still in the early stages of development, but have shown promise in clinical trials. The Neoantigen Cancer Vaccine market is expected to grow as more personalized cancer treatments become available. Companies in the market include Moderna, BioNTech, CureVac, and Inovio Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.